Difference between revisions of "Siltuximab (Sylvant)"
m |
m (→Also known as) |
||
| Line 16: | Line 16: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' CNTO 328 | + | *'''Code name:''' CNTO-328 |
*'''Brand name:''' Sylvant | *'''Brand name:''' Sylvant | ||
Latest revision as of 12:08, 19 August 2023
General information
Class/mechanism: Human-mouse chimeric monoclonal antibody which binds interleukin-6 (IL-6). Siltuximab prevents IL-6 from binding to soluble and membrane-bound IL-6 receptors. Blocking IL-6 activity interferes with its processes such immunoglobulin secretion. Systemic manifestations in patients with multicentric Castleman’s disease (MCD) has been associated with overproduction of IL-6.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2014-04-23: FDA approved for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. (Based on CR016705)
Also known as
- Code name: CNTO-328
- Brand name: Sylvant